Biogen Builds Out Neuroscience Niche With Ischemic Stroke Drug
Biogen acquired rights to Remedy's Cirara, a Phase III-ready candidate in development for large hemispheric infarction, a severe stroke where brain swelling causes high mortality.
Biogen acquired rights to Remedy's Cirara, a Phase III-ready candidate in development for large hemispheric infarction, a severe stroke where brain swelling causes high mortality.